This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Strength in Medical & Fluid Solutions Unit Drives Nordson: Can It Sustain?
by Zacks Equity Research
NDSN is gaining momentum as its Medical and Fluid Solutions segment delivers solid organic growth and margin expansion.
Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?
by Zacks Equity Research
DHR sees Biotechnology core revenues rise 6.5% in Q3 2025, fueled by bioprocessing demand, with approximately 5% growth expected in Q4.
InnovAge (INNV) Moves 7.8% Higher: Will This Strength Last?
by Zacks Equity Research
InnovAge (INNV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SOLV vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
SOLV vs. DHR: Which Stock Is the Better Value Option?
SOLV or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SOLV vs. DHR: Which Stock Is the Better Value Option?
Unlocking Danaher (DHR) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Explore Danaher's (DHR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Company News for Oct 22, 2025
by Zacks Equity Research
Companies in The News Are: KO, DHR, RTX, VST
Danaher Q3 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR Q3 earnings and sales beat estimates, driven by solid segment growth and stronger operating margins.